These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19721069)

  • 1. LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20.
    Tardif MR; Gilbert C; Thibault S; Fortin JF; Tremblay MJ
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4656-66. PubMed ID: 19721069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
    Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S
    Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane.
    Beauséjour Y; Tremblay MJ
    J Infect Dis; 2004 Sep; 190(5):894-902. PubMed ID: 15295693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitors of fusion: a new alternative in the treatment of HIV infection].
    Roca Villanueva B
    Med Clin (Barc); 2004 May; 122(17):659-60. PubMed ID: 15153345
    [No Abstract]   [Full Text] [Related]  

  • 7. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
    Pan C; Cai L; Lu H; Qi Z; Jiang S
    J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
    Pan C; Lu H; Qi Z; Jiang S
    AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1.
    Giguère JF; Tremblay MJ
    J Virol; 2004 Nov; 78(21):12062-5. PubMed ID: 15479847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
    Barretina J; Blanco J; Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
    Antivir Ther; 2003 Apr; 8(2):155-61. PubMed ID: 12741628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
    Svicher V; Alteri C; D'Arrigo R; Laganà A; Trignetti M; Lo Caputo S; Callegaro AP; Maggiolo F; Mazzotta F; Ferro A; Dimonte S; Aquaro S; di Perri G; Bonora S; Tommasi C; Trotta MP; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2816-23. PubMed ID: 19124665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.
    Tremblay CL; Poulin DL; Hicks JL; Selliah S; Chamberland A; Giguel F; Kollmann CS; Chou TC; Dong H; Hirsch MS
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3644-6. PubMed ID: 14576137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
    Ketas TJ; Klasse PJ; Spenlehauer C; Nesin M; Frank I; Pope M; Strizki JM; Reyes GR; Baroudy BM; Moore JP
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):177-86. PubMed ID: 12689409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
    Ketas TJ; Frank I; Klasse PJ; Sullivan BM; Gardner JP; Spenlehauer C; Nesin M; Olson WC; Moore JP; Pope M
    J Virol; 2003 Feb; 77(4):2762-7. PubMed ID: 12552019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.